PTAB rejects Vimovo IPR trial
Celgene fends off Kyle Bass challenge
Svetlana Lukienko / Shutterstock.com
Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review (IPR) challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kyle Bass; PTAB; Vimovo; IPR; Coalition for Affordable Drugs; Pozen